Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 176

Results For "disease"

2672 News Found

Jemincare inks licensing deal for prostate cancer drug with Roche
News | August 19, 2022

Jemincare inks licensing deal for prostate cancer drug with Roche

Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.


Growing investment in biotech startups likely to make CAR-T therapies affordable in India, says GlobalData
Startup | August 19, 2022

Growing investment in biotech startups likely to make CAR-T therapies affordable in India, says GlobalData

GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.


FDA accepts submission of olaparib in combination with abiraterone and prednisone for prostate cancer
Drug Approval | August 17, 2022

FDA accepts submission of olaparib in combination with abiraterone and prednisone for prostate cancer

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations


Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology
Biotech | August 17, 2022

Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology

Collaboration supports multiple discovery efforts, including vaccines


Short Wave Pharma signs clinical trial agreement with the Sheeba Research Fund
Clinical Trials | August 16, 2022

Short Wave Pharma signs clinical trial agreement with the Sheeba Research Fund

The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.


PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital
Biotech | August 16, 2022

PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital

Company appoints five new independent directors to reconstituted board


Fish & Richardson secures win for Exela Pharma Sciences in ELCYS patent infringement litigation
News | August 16, 2022

Fish & Richardson secures win for Exela Pharma Sciences in ELCYS patent infringement litigation

ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions


QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency
News | August 16, 2022

QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency

QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms


Yashoda Hospitals successfully performs bariatric surgery
Hospitals | August 15, 2022

Yashoda Hospitals successfully performs bariatric surgery

Man lost 54 Kgs in 6 months with MGB procedure


Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
News | August 13, 2022

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease